A randomised placebo-controlled, double-blind phase II study to explore the safety, efficacy, and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease and motor symptoms (“KHENERGYC”)

Peer Review reports

Original Submission
1 Feb 2022	Submitted	Original manuscript
31 Mar 2022	Author responded	Author comments - Jan Smeitink
Resubmission - Version 2
31 Mar 2022	Submitted	Manuscript version 2
11 Apr 2022	Author responded	Author comments - Jan Smeitink
Resubmission - Version 3
11 Apr 2022	Submitted	Manuscript version 3
12 Apr 2022	Author responded	Author comments - Jan Smeitink
Resubmission - Version 4
12 Apr 2022	Submitted	Manuscript version 4
Publishing
18 Apr 2022	Editorially accepted
27 Apr 2022	Article published	10.1186/s12883-022-02685-3

Back to article page